Registered title, quoted from ClinicalTrials.gov
RaSOLVE: 125I Radioactive Seed Marking Effects on Pathological Complete Response Rate and Prognosis Post-Neoadjuvant Therapy in Early/Advanced Breast Cancer
An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Shandong Cancer Hospital and Institute; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07269691, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 8
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (8 points)Hide the checklist
18 years to 70 years; sex: women only
Registered eligibility fields
Pathologically confirmed, previously untreated, unilateral primary invasive breast cancer.
Inclusion criterion 3
Clinical stage cT1cN1-2M0 or cT2-3N0-2M0 (AJCC 8th edition).
Inclusion criterion 4
Negative serum pregnancy test within 3 days prior to first treatment for women of childbearing potential and agreement to use effective contraception.
Inclusion criterion 16
Prior systemic chemotherapy, targeted therapy, immunotherapy, or radiotherapy within 1 year.
Exclusion criterion 3
ECOG performance status 0-1.
Inclusion criterion 2
Hemoglobin ≥ 90 g/L
Inclusion criterion 6
ANC ≥ 1.5×10⁹/L; Lymphocyte count ≥ 0.5×10⁹/L
Inclusion criterion 7
Platelet count ≥ 100×10⁹/L
Inclusion criterion 8
WBC 3.0-15×10⁹/L
Inclusion criterion 9
ALT, AST ≤ 2.5×ULN; ALP ≤ 2.5×ULN; TBIL ≤ 1.5×ULN
Inclusion criterion 10
Serum creatinine ≤ 1.5×ULN and creatinine clearance ≥ 60 mL/min
Inclusion criterion 11
PT, APTT ≤ 1.5×ULN
Inclusion criterion 12
Coagulation abnormalities (INR > 1.5 or APTT > 1.5×ULN).
Exclusion criterion 18
Any malignancy diagnosed within the past 5 years except cured cervical carcinoma in situ or non-melanoma skin cancer.
Exclusion criterion 2
Active HBV, HCV, or HIV infection.
Exclusion criterion 14
Pregnancy, breastfeeding, or planning pregnancy.
Exclusion criterion 23
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07269691, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Female patients aged 18 to 70 years.
- ECOG performance status 0-1.
- Pathologically confirmed, previously untreated, unilateral primary invasive breast cancer.
- Clinical stage cT1cN1-2M0 or cT2-3N0-2M0 (AJCC 8th edition).
- Adequate organ function within 7 days prior to randomization:
- Hemoglobin ≥ 90 g/L
- ANC ≥ 1.5×10⁹/L; Lymphocyte count ≥ 0.5×10⁹/L
- Platelet count ≥ 100×10⁹/L
- WBC 3.0-15×10⁹/L
- ALT, AST ≤ 2.5×ULN; ALP ≤ 2.5×ULN; TBIL ≤ 1.5×ULN
- Serum creatinine ≤ 1.5×ULN and creatinine clearance ≥ 60 mL/min
- PT, APTT ≤ 1.5×ULN
- Urine protein < 2+ or 24-hour urine protein ≤ 1 g
- LVEF ≥ 55%
- QTcF < 470 ms
- Negative serum pregnancy test within 3 days prior to first treatment for women of childbearing potential and agreement to use effective contraception.
- Willing and able to sign informed consent.
Exclusion Criteria:
- Bilateral breast cancer or history of DCIS, LCIS, invasive breast cancer, or metastatic breast cancer.
- Any malignancy diagnosed within the past 5 years except cured cervical carcinoma in situ or non-melanoma skin cancer.
- Prior systemic chemotherapy, targeted therapy, immunotherapy, or radiotherapy within 1 year.
- Prior exposure to anthracyclines, taxanes, or platinum agents.
- Primary or secondary immunodeficiency; uncontrolled autoimmune disease (except controlled hypothyroidism or type 1 diabetes).
- Interstitial lung disease or severe chronic lung disease.
- Clinically significant cardiovascular disease, including:
- NYHA class ≥ III
- Myocardial infarction or stroke within 3 months
- Uncontrolled hypertension
- Clinically significant arrhythmia or heart failure
- Arterial/venous thrombosis within 3 months.
- Vaccination with live attenuated vaccine within 28 days.
- Active HBV, HCV, or HIV infection.
- Major surgery within 28 days (except diagnostic procedures).
- Severe infection within 4 weeks or systemic antibiotic-treated infection within 2 weeks.
- History of bone marrow or organ transplantation.
- Coagulation abnormalities (INR > 1.5 or APTT > 1.5×ULN).
- Peripheral neuropathy ≥ Grade 2.
- Treatment with systemic immunostimulatory agents within 4 weeks or immunosuppressive agents within 2 weeks.
- Known allergy to study agents.
- Participation in another clinical trial within 4 weeks.
- Pregnancy, breastfeeding, or planning pregnancy.
- Substance abuse or psychiatric conditions that may affect compliance.
- Any condition that, in the investigator's judgment, makes the patient unsuitable for the study.
Quoted from ClinicalTrials.gov, NCT07269691, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07269691, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.